NAUT earnings: next report 2026-07-28, real EPS beat/miss history, analyst consensus Buy, P/E -3.70. Updated 2026-07-23.
Nautilus Biotechnolgy (NAUT) Research Hub
Nautilus Biotechnolgy (NAUT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.02 USD (-8.93%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.70, market cap 0.22B. This hub links to the full technical, earnings and options research available for NAUT.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.02 USD (-8.93%) |
| 52-week range | 0.841 USD – 2.41 USD |
| Trend regime | Range |
| 14-day RSI | 59.2 (Bullish) |
| Trailing P/E | -3.70 |
| Market cap | 0.22B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-28 |
Available research for NAUT
Covered Call on NAUT: how it works, illustrative setup around the real 1.02 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NAUT: how it works, illustrative setup around the real 1.02 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NAUT: how it works, illustrative setup around the real 1.02 USD price, max profit/loss, breakeven and when to use it. Educational.
NAUT technical analysis: range, last 1.02 USD, RSI 59.2, 52w range 0.841 USD–2.41 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NAUT in?
Nautilus Biotechnolgy (NAUT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is NAUT in an uptrend or downtrend?
As of 2026-09-11, NAUT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NAUT's trailing P/E ratio?
NAUT's trailing P/E is -3.70, with a market cap of 0.22B. See the earnings research page for full valuation detail.
When does NAUT next report earnings?
NAUT is next scheduled to report earnings on 2026-07-28, with a consensus EPS estimate of -0.135 USD.